Program Description
Activation of the Janus-associated kinase (JAK)/signal transducers and activators of the transcription pathway has been shown to play a crucial role in disease development and progression of myelofibrosis (MF). JAK inhibitors have emerged as guideline-recommended treatment options for patients with MF who are not eligible for allogeneic stem cell transplantation, yet nearly half of patients experience treatment failure. Oncology pharmacists must be prepared to navigate the management of adverse effects, considerations for dose tapering or switching, and other clinical challenges associated with JAK inhibitor treatment failure to prevent treatment discontinuation. Along with clinical efficacy and real-world data, this program will additionally review best practices for oncology pharmacists in the provision of supportive care to optimize management of JAK inhibitors in patients with MF.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: December 4, 2023
Expiration date: December 4, 2024
Time to complete activity: 1.0 hour
Learner level: Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Apply clinical evidence to the selection of Janus-associated kinase (JAK) inhibitors in the management of myelofibrosis
- Ensure timely interventions after JAK inhibitor failure to mitigate disease progression
- Construct comprehensive care plans for patients with myelofibrosis, incorporating supportive care interventions, symptom management strategies, and appropriate monitoring for adverse effects
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
